Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer

NCT01803269 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT01803269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01803269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Terminated
Start date
January 16, 2013
Completion date
March 30, 2016
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer, recurrent small cell lung cancer